Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma

The next frontier towards a cure for B-cell non-Hodgkin lymphomas (B-NHL) is autologous cellular immunotherapy such as immune checkpoint blockade (ICB), bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cells. While highly successful in various solid malignancies and in aggressive...

Full description

Bibliographic Details
Main Authors: Jaco A. C. van Bruggen, Anne W. J. Martens, Sanne H. Tonino, Arnon P. Kater
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
immunotherapy
B-NHL
CLL
CAR T-cells
immune checkpoint blockade
bispecific antibodies
Online Access:https://www.mdpi.com/2072-6694/12/12/3837

Internet

https://www.mdpi.com/2072-6694/12/12/3837

Similar Items